CHMP recommends Incresync (Takeda) for Type 2 Diabetes
On 25 July 2013, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for Incresync, 12.5 mg / 45 mg, 12.5 mg / 30 mg, 25 mg / 45 mg and 25 mg / 30 mg, film-coated tablet from Takeda and intended for the treatment of Type 2 Diabetes Mellitus.
The active substances of Incresync are alogliptin/pioglitazone (A10BD09), a combination of two blood glucose-lowering products: alogliptin is a dipeptidyl peptidase 4 (DPP 4) inhibitor which reduces the cleavage and inactivation of the active (intact) form of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), producing an elevation of incretin concentrations that leads to an enhancement of glucose-dependent insulin secretion and a reduction in glucagon release. Pioglitazone is a thiazolidinedione and acts via activation of a specific nuclear receptor (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells.
Alogliptin plus pioglitazone is FDA approved as Oseni.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins